生物类似药作为原研生物药的 “孪生兄弟”,在专利到期后为患者提供了可及性更高的治疗选择。生物类似药是指在质量、安全性和疗效上与已获批原研生物药(参考产品)高度相似的药物,但并非完全 identical 的复制版。两者的关键差异在于:生物类似药允许存在细微结构差异,只要这些差异不会对临床效果产生显著影响。近年来,我国在生物类似药领域成绩斐然,众多企业的积极投入与创新,推动了该领域的快速发展。据悉,自...
Source Link生物类似药作为原研生物药的 “孪生兄弟”,在专利到期后为患者提供了可及性更高的治疗选择。生物类似药是指在质量、安全性和疗效上与已获批原研生物药(参考产品)高度相似的药物,但并非完全 identical 的复制版。两者的关键差异在于:生物类似药允许存在细微结构差异,只要这些差异不会对临床效果产生显著影响。近年来,我国在生物类似药领域成绩斐然,众多企业的积极投入与创新,推动了该领域的快速发展。据悉,自...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.